# Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

> **NCT01254279** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 984 (actual)

## Conditions studied

- Prostate Cancer Metastatic

## Interventions

- **DRUG:** CABAZITAXEL

## Key facts

- **NCT ID:** NCT01254279
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 984 (ACTUAL)
- **Last updated:** 2015-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01254279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01254279, "Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen". Retrieved via AI Analytics 2026-09-14 from https://api.ai-analytics.org/clinical/NCT01254279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*